Mechanistic and inhibition studies on isocitrate dehydrogenase 1
<p>Genes encoding for IDH1 and IDH2 are frequently mutated in multiple cancer types including gliomas and AML. IDH variants, notably R132H IDH1, result in a gain-offunction leading to substantially enhanced production of the ‘oncometabolite’, 2- hydroxyglutarate. Drug development by pharmaceut...
主要作者: | Liu, S |
---|---|
其他作者: | Schofield, C |
格式: | Thesis |
語言: | English |
出版: |
2019
|
相似書籍
-
The studies on the mechanism and inhibition of Isocitrate Dehydrogenases
由: Liu, X
出版: (2022) -
Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
由: Li Su, et al.
出版: (2020-04-01) -
How robust are the data in vorasidenib for isocitrate dehydrogenase-1 or isocitrate dehydrogenase-2 mutant low-grade glioma?
由: Eric T Wong
出版: (2023-01-01) -
Highlighting the mechanistic role of Olutasidenib (FT-2102) in the selective inhibition of mutated isocitrate dehydrogenase 1 (mIDH1) in cancer therapy
由: Elliasu Y. Salifu, et al.
出版: (2022-01-01) -
Differentiating inhibition selectivity and binding affinity of isocitrate dehydrogenase 1 variant inhibitors
由: Liu, S, et al.
出版: (2023)